Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaJoaquim Bellmunt, Dean F. Bajorin, Ronald de Wit et al.|New England Journal of Medicine|2017Cited by 3.4k
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 studyArjun Vasant Balar, Joaquim Bellmunt, Daniel Castellano et al.|The Lancet Oncology|2017Cited by 1.3k
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 studyArjun Vasant Balar, Ronald de Wit, Ashish M. Kamat et al.|The Lancet Oncology|2021Cited by 532
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-upYves Fradet, Dean F. Bajorin, David J. Vaughn et al.|Annals of Oncology|2019Cited by 484
Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trialR.T.D. Oliver, SP Stenning, MD Mason et al.|The Lancet|2005Cited by 447